Inpefa
Total Payments
$2.3M
Transactions
18,951
Doctors
9,793
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.7M | 3,666 | 1,888 |
| 2023 | $647,382 | 15,285 | 8,501 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $1.4M | 517 | 62.9% |
| Food and Beverage | $539,605 | 17,484 | 23.4% |
| Travel and Lodging | $190,798 | 924 | 8.3% |
| Consulting Fee | $99,930 | 20 | 4.3% |
| Unspecified | $15,764 | 2 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $5,000 | 1 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,213 | 2 | 0.1% |
| Grant | $1,200 | 1 | 0.1% |
Payments by Type
General
$2.3M
18,949 transactions
Research
$15,764
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Effects of Sotagliflozin in regulation of clotting and thrombotic Risk | Lexicon Pharmaceuticals, Inc. | $11,164 | 0 |
| LX9211.1-204-DPN-A Phase 2b, Dose-ranging, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study with an Open0label Extension in Patients with Diabetic Peripheral Neurophathic Pain. | Lexicon Pharmaceuticals, Inc. | $4,600 | 0 |
Top Doctors Receiving Payments for Inpefa — Page 392
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Cardiovascular Disease | Lafayette, LA | $12.71 | 1 |
| , MD | Cardiovascular Disease | Lewisburg, PA | $12.71 | 1 |
| , FNP | Family | Lafayette, LA | $12.71 | 1 |
| , M.D | Cardiovascular Disease | Plano, TX | $12.71 | 1 |
| , MD | Internal Medicine | Mesa, AZ | $12.71 | 1 |
| , NP | Family | Burton, MI | $12.70 | 1 |
| , M.D | Cardiovascular Disease | Chesterfield, MO | $12.69 | 1 |
| , MD | Cardiovascular Disease | Pepper Pike, OH | $12.69 | 1 |
| , MD | Cardiovascular Disease | Chesterfield, MO | $12.69 | 1 |
| , MD | Internal Medicine | Philadelphia, PA | $11.86 | 1 |
| , MSFNP-BC | Family | Tiverton, RI | $11.58 | 1 |
| , PA-C | Physician Assistant | Rockford, IL | $11.44 | 1 |
| , M.D | Cardiovascular Disease | Hattiesburg, MS | $11.01 | 1 |
| , MD | Cardiovascular Disease | Bridgeport, CT | $10.96 | 2 |
| Jacqueline Messing | Family | Saginaw, MI | $10.15 | 1 |
| , CNP | Family | Saginaw, MI | $10.15 | 1 |
| , ACNP | Acute Care | Summit, MS | $7.75 | 1 |
| , M.D | Cardiovascular Disease | Winchester, IN | $6.24 | 1 |
| , M.D | Cardiovascular Disease | Savannah, GA | $3.66 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 9,793
- Transactions 18,951
About Inpefa
Inpefa is a drug associated with $2.3M in payments to 9,793 healthcare providers, recorded across 18,951 transactions in the CMS Open Payments database. The primary manufacturer is Lexicon Pharmaceuticals, Inc..
Payment data is available from 2023 to 2024. In 2024, $1.7M was paid across 3,666 transactions to 1,888 doctors.
The most common payment nature for Inpefa is "Honoraria" ($1.4M, 62.9% of total).
Inpefa is associated with 2 research studies, including "Effects of Sotagliflozin in regulation of clotting and thrombotic Risk" ($11,164).